Different Angiogenic Potential in Low and High Grade Sporadic Clear Cell Renal Cell Carcinoma Is Not Related to Alterations in the von Hippel–Lindau Gene
暂无分享,去创建一个
T. Roskams | G. G. Van den Eynden | M. van Engeland | P. Vermeulen | I. J. van Vlodrop | M. Baldewijns | K. Smits | H. V. Van Poppel | A. D. de Bruïne | F. Schot
[1] S. Richard. VHL (von Hippel-Lindau tumor suppressor) , 2011 .
[2] P. A. van den Brandt,et al. Genetic and Epigenetic Alterations in the von Hippel-Lindau Gene: the Influence on Renal Cancer Prognosis , 2008, Clinical Cancer Research.
[3] D. Chung,et al. Hypoxia Inducible Factor-1–Independent Pathways in Tumor Angiogenesis , 2007, Clinical Cancer Research.
[4] T. Roskams,et al. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT–PCR mRNA expression profile , 2007, British Journal of Cancer.
[5] John P A Ioannidis,et al. Is molecular profiling ready for use in clinical decision making? , 2007, The oncologist.
[6] W. Kaelin. The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma , 2007, Clinical Cancer Research.
[7] K. Grankvist,et al. Hypoxia-Inducible Factor 1α Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray , 2006 .
[8] Kentaro Takahashi,et al. [Von Hippel-Lindau disease]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[9] M. Oya,et al. Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α , 2006 .
[10] C. Taylor,et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. , 2006, Cancer research.
[11] Pei-yin Lin,et al. Kidney cancer: identification of novel targets for therapy. , 2006, Kidney international.
[12] E. van Marck,et al. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer , 2005, British Journal of Cancer.
[13] N. Hay,et al. The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.
[14] J. Ioannidis. Why Most Published Research Findings Are False , 2005, PLoS medicine.
[15] F. Marshall. Promoter hypermethylation profile of kidney cancer. , 2005, The Journal of urology.
[16] Patrick H. Maxwell,et al. Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.
[17] P. A. van den Brandt,et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands cohort study , 2005, BMC Cancer.
[18] K. Grankvist,et al. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] W. Kaelin,et al. Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Schalken,et al. Strict regulation of CAIXG250/MN by HIF-1α in clear cell renal cell carcinoma , 2004, Oncogene.
[21] R. Uzzo,et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. , 2003, Cancer research.
[22] R. Klausner,et al. Studying cancer families to identify kidney cancer genes. , 2003, Annual review of medicine.
[23] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[24] E. Messing,et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. , 2003, The Journal of urology.
[25] R Alexandra Goldbohm,et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. , 2003, Cancer research.
[26] J. Klco,et al. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. , 2003, Molecular cancer research : MCR.
[27] E. Stanbridge,et al. Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. , 2003, Cancer research.
[28] A. Harris,et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. , 2002, Cancer research.
[29] T. Shuin,et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters , 2002, Genes, chromosomes & cancer.
[30] M. Esumi,et al. Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma. , 2002, The Journal of urology.
[31] Holger Moch,et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma , 2002, The Journal of pathology.
[32] A. Harris,et al. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. , 2001, Cancer research.
[33] H. Moch,et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. , 2001, Cancer research.
[34] H. Gröne,et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. , 2001, Cancer research.
[35] W. Kaelin,et al. The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.
[36] A. Harris,et al. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling , 2000, Oncogene.
[37] L. Poellinger,et al. Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor protein , 2000, The EMBO journal.
[38] M. Ivan,et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.
[39] P. Carmeliet,et al. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis (vol 394, pg 485, 1998) , 1998 .
[40] L. Huang,et al. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .
[41] S. Richard,et al. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. , 1997, American journal of human genetics.
[42] W. Linehan,et al. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. , 1996, The American journal of pathology.
[43] R. Klausner,et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[44] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[45] R. Greenberg,et al. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. , 1995, Cancer research.
[46] K. Kok,et al. Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis. , 1995, Genes, chromosomes & cancer.
[47] O Yoshida,et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. , 1995, Cancer research.
[48] M. Ferguson-Smith,et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. , 1994, Human molecular genetics.
[49] J. Herman,et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[50] J. Brooks,et al. Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.
[51] B. Teh,et al. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. , 2008, Cancer research.
[52] D. Walsh. Pathophysiological mechanisms of angiogenesis. , 2007, Advances in clinical chemistry.
[53] M. Oya,et al. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. , 2007, Carcinogenesis.
[54] J. Ioannidis. Molecular Bias , 2005, European Journal of Epidemiology.
[55] H. Brauch,et al. Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p , 2004, World Journal of Urology.
[56] J. Schalken,et al. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. , 2004, Oncogene.
[57] F. Waldman,et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. , 1996, Cancer research.
[58] W. Linehan,et al. Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan , 1996, Human mutation.